Sales of BYERUS® and Cross-Industry Applications of Antiviral Technology
First written in FY2021. 3 of 4 entries say "Restated". Latest entry: FY2023-Q1.
1 other company's latest entry also says "Restated".
- FY2023-Q1RestatedAnnual report
「We are advancing the application of the antiviral technology developed through the development of the high-performance antiviral mask “BYERUS®,” launched during the COVID-19 pandemic, to other fields, including interiors and nursing care.」
The policy of applying the antiviral technology developed through BYERUS® to fields including interiors and nursing care continues. - FY2022-Q2RestatedAnnual report
「We are advancing the application of the antiviral technology developed through the development of the high-performance antiviral mask “BYERUS®,” launched during the COVID-19 pandemic, to other fields, including interiors and nursing care.」
The policy of applying the antiviral technology developed through BYERUS® to fields including interiors and nursing care continues. - FY2022-Q1RestatedAnnual report
「We are advancing the application of the antiviral technology developed through the development of the high-performance antiviral mask “BYERUS®,” launched during the COVID-19 pandemic, to other fields, including interiors and nursing care.」
The policy of applying the antiviral technology developed through BYERUS® to fields including interiors and nursing care continues. - FY2021First statedAnnual report
「Sales of the high-performance antiviral mask “BYERUS®,” launched during the COVID-19 pandemic, have been solid. Going forward, the Group will apply the antiviral technology developed for BYERUS® in other fields, including interiors and nursing care.」
The Group launched a high-performance antiviral mask and stated that sales were solid, while also planning to apply the technology developed for it in interiors and nursing care.